Notice of Results

RNS Number : 6267Q

Genedrive PLC

28 October 2021

 

genedrive plc

("genedrive" or the "Company")

Notice of Results

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2021 on Tuesday 9 November 2021.

genedrive will be hosting a live online presentation on Thursday, 11 November at 14:00, delivered by David Budd, CEO.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via:

https://www.investormeetcompany.com/genedrive-plc/register-investor

Investors who already follow genedrive plc on the Investor Meet Company platform will automatically be invited.

For further details please contact:

genedrive plc	[phone]
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	[phone]
James Steel
finnCap (Joint Broker)	[phone]
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy	[phone] / [phone]

About genedrive plc ( http://www.genedriveplc.com )  genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, Antibiotic Induced Hearing Loss and certain military biological targets. The Company released a high throughput SARS-CoV-2 assay in 2020 and has a point of care version of the SARS-Cov-2 test due on market during 2021.

 

END

 

 

NORMPBITMTJTBPB